.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Covington
Fish and Richardson
QuintilesIMS
Dow
Medtronic
Deloitte
Farmers Insurance
Baxter

Generated: November 22, 2017

DrugPatentWatch Database Preview

Ani Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS INC, and when can generic versions of ANI PHARMS INC drugs launch?

ANI PHARMS INC has one hundred and twenty-two approved drugs.

There is one US patent protecting ANI PHARMS INC drugs.

There are fourteen patent family members on ANI PHARMS INC drugs in eleven countries and eighteen supplementary protection certificates in nine countries.

Summary for Ani Pharms Inc

International Patents:14
US Patents:1
Tradenames:63
Ingredients:59
NDAs:122
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc
ACETOHEXAMIDE
acetohexamide
TABLET;ORAL070869-001Feb 9, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
VANCOCIN HYDROCHLORIDE
vancomycin hydrochloride
INJECTABLE;INJECTION060180-002Mar 21, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
FLUVOXAMINE MALEATE
fluvoxamine maleate
TABLET;ORAL075897-003Jan 25, 2001ABRXNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
INDAPAMIDE
indapamide
TABLET;ORAL074498-001Oct 31, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
DESIPRAMINE HYDROCHLORIDE
desipramine hydrochloride
TABLET;ORAL071803-005May 29, 1997RXNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
ZONISAMIDE
zonisamide
CAPSULE;ORAL077641-003Dec 22, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
LORAZEPAM
lorazepam
TABLET;ORAL077396-003Dec 13, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
ALPRAZOLAM
alprazolam
TABLET, EXTENDED RELEASE;ORAL077979-004Feb 28, 2007DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
THIORIDAZINE HYDROCHLORIDE
thioridazine hydrochloride
TABLET;ORAL088271-001Apr 14, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
ALPRAZOLAM
alprazolam
TABLET, EXTENDED RELEASE;ORAL077725-002Jul 31, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc
LITHOBID
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL018027-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-003Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-001Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 1987► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ani Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086Timed, sustained release systems for propranolol► Subscribe
9,358,214Timed, sustained release systems for propranolol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ani Pharms Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1432411► Subscribe
Japan4369752► Subscribe
Spain2333306► Subscribe
Norway20041740► Subscribe
MexicoPA04003234► Subscribe
World Intellectual Property Organization (WIPO)03028708► Subscribe
South Korea101090719► Subscribe
Norway335070► Subscribe
Japan2005508922► Subscribe
Canada2462637► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ani Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
80045Netherlands► SubscribePRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Fuji
Express Scripts
Chubb
Queensland Health
Cipla
Teva
McKesson
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot